Alkaloids as Additional Weapons in the Fight against Breast Cancer: A Review

Chahat, B.; Bhatia, R.; Kumar, B. p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies. Eur. J. Med. Chem., 2023, 247, 115020.
[http://dx.doi.org/10.1016/j.ejmech.2022.115020] [PMID: 36543034]

Taruneshwar Jha, K.; Shome, A. Chahat; Chawla, P.A. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship. Bioorg. Chem., 2023, 138, 106680.
[http://dx.doi.org/10.1016/j.bioorg.2023.106680] [PMID: 37336103]

Dhyani, P.; Quispe, C.; Sharma, E.; Bahukhandi, A.; Sati, P.; Attri, D.C.; Szopa, A.; Sharifi-Rad, J.; Docea, A.O.; Mardare, I.; Calina, D.; Cho, W.C. Anticancer potential of alkaloids: A key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int., 2022, 22(1), 206.
[http://dx.doi.org/10.1186/s12935-022-02624-9] [PMID: 35655306]

Vidyasekar, P.; Shyamsunder, P.; Arun, R.; Santhakumar, R.; Kapadia, N.K.; Kumar, R.; Verma, R.S. Genome wide expression profiling of cancer cell lines cultured in microgravity reveals significant dysregulation of cell cycle and MicroRNA gene networks. PLoS One, 2015, 10(8), e0135958.
[http://dx.doi.org/10.1371/journal.pone.0135958] [PMID: 26295583]

Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]

El-Helby, A.G.A.; Sakr, H.; Ayyad, R.R.; Mahdy, H.A.; Khalifa, M.M.; Belal, A.; Rashed, M.; El-Sharkawy, A.; Metwaly, A.M.; Elhendawy, M.A.; Radwan, M.M.; ElSohly, M.A.; Eissa, I.H. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. Bioorg. Chem., 2020, 103, 104233.
[http://dx.doi.org/10.1016/j.bioorg.2020.104233] [PMID: 32882440]

WHO. Assessing national capacity for the prevention and control of noncommunicable diseases: Report of the 2019 global survey. , 2020. Available from: https://www.who.int/publications/i/item/9789240002319

Kaushik, I.; Ramachandran, S.; Prasad, S.; Srivastava, S.K. Drug rechanneling: A novel paradigm for cancer treatment. In: Seminars in Cancer Biology; Elsevier, 2021; 68, pp. 279-290.

Kulothungan, V.; Sathishkumar, K.; Leburu, S.; Ramamoorthy, T.; Stephen, S.; Basavarajappa, D.; Tomy, N.; Mohan, R.; Menon, G.R.; Mathur, P. Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program. BMC Cancer, 2022, 22(1), 527.
[http://dx.doi.org/10.1186/s12885-022-09578-1] [PMID: 34979993]

Kumar, B.; Singh, S.; Skvortsova, I.; Kumar, V. Promising targets in anti-cancer drug development: Recent updates. Curr. Med. Chem., 2017, 24(42), 4729-4752.
[PMID: 28393696]

Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.

Wulfkuhle, J.D.; Liotta, L.A.; Petricoin, E.F. Proteomic applications for the early detection of cancer. Nat. Rev. Cancer, 2003, 3(4), 267-275.
[http://dx.doi.org/10.1038/nrc1043] [PMID: 12671665]

Hortobagyi, G.N.; de la Garza Salazar, J.; Pritchard, K.; Amadori, D.; Haidinger, R.; Hudis, C.A.; Khaled, H.; Liu, M.C.; Martin, M.; Namer, M.; O’Shaughnessy, J.A.; Shen, Z.Z.; Albain, K.S. The global breast cancer burden: Variations in epidemiology and survival. Clin. Breast Cancer, 2005, 6(5), 391-401.
[http://dx.doi.org/10.3816/CBC.2005.n.043] [PMID: 16381622]

Lei, S.; Zheng, R.; Zhang, S.; Chen, R.; Wang, S.; Sun, K.; Zeng, H.; Wei, W.; He, J. Breast cancer incidence and mortality in women in China: Temporal trends and projections to 2030. Cancer Biol. Med., 2021, 18(3), 900-909.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0523] [PMID: 34002584]

Smith, R.A.; von Eschenbach, A.C.; Wender, R.; Levin, B.; Byers, T.; Rothenberger, D.; Brooks, D.; Creasman, W.; Cohen, C.; Runowicz, C.; Saslow, D.; Cokkinides, V.; Eyre, H. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001--testing for early lung cancer detection. CA Cancer J. Clin., 2001, 51(1), 38-75.
[http://dx.doi.org/10.3322/canjclin.51.1.38] [PMID: 11577479]

Alzain, A.A.; Brisson, L.; Delaye, P.O.; Pénichon, M.; Chadet, S.; Besson, P.; Chevalier, S.; Allouchi, H.; Mohamed, M.A.; Roger, S.; Enguehard-Gueiffier, C. Bioinspired imidazo[1,2-a:4,5-c′]dipyridines with dual antiproliferative and anti-migrative properties in human cancer cells: The SAR investigation. Eur. J. Med. Chem., 2021, 218, 113258.
[http://dx.doi.org/10.1016/j.ejmech.2021.113258] [PMID: 33813152]

Sun, M.; Zhang, Y.; Qin, J.; Ba, M.; Yao, Y.; Duan, Y.; Liu, H.; Yu, D. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization. Bioorg. Chem., 2021, 113, 104988.
[http://dx.doi.org/10.1016/j.bioorg.2021.104988] [PMID: 34034135]

Bonapace, L.; Coissieux, M.M.; Wyckoff, J.; Mertz, K.D.; Varga, Z.; Junt, T.; Bentires-Alj, M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature, 2014, 515(7525), 130-133.
[http://dx.doi.org/10.1038/nature13862] [PMID: 25337873]

Niu, Y.; Bao, L.; Chen, Y.; Wang, C.; Luo, M.; Zhang, B.; Zhou, M.; Wang, J.E.; Fang, Y.V.; Kumar, A.; Xing, C.; Wang, Y.; Luo, W. HIF2-induced long noncoding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis. Cancer Res., 2020, 80(5), 964-975.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-1532] [PMID: 31900259]

Lucas, M.C.; Tan, S.L. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: Will promise meet expectations? Future Med. Chem., 2014, 6(16), 1811-1827.
[http://dx.doi.org/10.4155/fmc.14.126] [PMID: 25407369]

Beutler, J.A. Natural products as a foundation for drug discovery. Curr. Protocols Pharmacol., 2009, 46(1), 11-19.
[http://dx.doi.org/10.1002/0471141755.ph0911s46]

Sharifi-Rad, J.; Quispe, C.; Imran, M.; Rauf, A.; Nadeem, M.; Gondal, T.A.; Ahmad, B.; Atif, M.; Mubarak, M.S.; Sytar, O. Genistein: An integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid. Med. Cell. Longev., 2021, 2021, 3268136.
[http://dx.doi.org/10.1155/2021/3268136]

Croteau, R.; Kutchan, T.M.; Lewis, N.G. Natural products (secondary metabolites). Plant Mol. Biol., 2000, 24, 1250-1319.

Williams, D.H.; Stone, M.J.; Hauck, P.R.; Rahman, S.K. Why are secondary metabolites (natural products) biosynthesized? J. Nat. Prod., 1989, 52(6), 1189-1208.
[http://dx.doi.org/10.1021/np50066a001] [PMID: 2693613]

Rajput, A.; Sharma, R.; Bharti, R. Pharmacological activities and toxicities of alkaloids on human health. Mater. Today Proc., 2022, 48, 1407-1415.
[http://dx.doi.org/10.1016/j.matpr.2021.09.189]

Debnath, B.; Singh, W.S.; Das, M.; Goswami, S.; Singh, M.K.; Maiti, D.; Manna, K. Role of plant alkaloids on human health: A review of biological activities. Mater. Today Chem., 2018, 9, 56-72.
[http://dx.doi.org/10.1016/j.mtchem.2018.05.001]

Berchtold, M.W.; Villalobo, A. The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. Biochim. Biophys. Acta Mol. Cell Res., 2014, 1843(2), 398-435.
[http://dx.doi.org/10.1016/j.bbamcr.2013.10.021] [PMID: 24188867]

Reed, J.C. Apoptosis-targeted therapies for cancer. Cancer Cell, 2003, 3(1), 17-22.
[http://dx.doi.org/10.1016/S1535-6108(02)00241-6] [PMID: 12559172]

Kato, Y.; Maeda, T.; Suzuki, A.; Baba, Y. Cancer metabolism: New insights into classic characteristics. Jpn. Dent. Sci. Rev., 2018, 54(1), 8-21.
[http://dx.doi.org/10.1016/j.jdsr.2017.08.003] [PMID: 29628997]

Habli, Z.; Toumieh, G.; Fatfat, M.; Rahal, O.; Gali-Muhtasib, H. Emerging cytotoxic alkaloids in the battle against cancer: Overview of molecular mechanisms. Molecules, 2017, 22(2), 250.
[http://dx.doi.org/10.3390/molecules22020250] [PMID: 28208712]

Mohapatra, P.; Singh, P.; Singh, D.; Sahoo, S.; Sahoo, S.K. Phytochemical based nanomedicine: A panacea for cancer treatment, present status and future prospective. In: Open- Nano; Elsevier, 2022; 7, p. 100055.

Khatoon, E.; Banik, K.; Harsha, C.; Sailo, B.L.; Thakur, K.K.; Khwairakpam, A.D.; Vikkurthi, R.; Devi, T.B.; Gupta, S.C.; Kunnumakkara, A.B. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin. Cancer Biol., 2022, 80, 306-339.
[http://dx.doi.org/10.1016/j.semcancer.2020.06.014] [PMID: 32610149]

Thundimadathil, J. Cancer treatment using peptides: Current therapies and future prospects. J. Amino Acids, 2012, 2012, 967347.

Kim, D.B.; Lee, D.K.; Cheon, C.; Ribeiro, R.I.M.A.; Kim, B. Natural products for liver cancer treatment: From traditional medicine to modern drug discovery. Nutrients, 2022, 14(20), 4252.
[http://dx.doi.org/10.3390/nu14204252] [PMID: 36296934]

Usman, M.; Khan, W.R.; Yousaf, N.; Akram, S.; Murtaza, G.; Kudus, K.A.; Ditta, A.; Rosli, Z.; Rajpar, M.N.; Nazre, M. Exploring the phytochemicals and anti-cancer potential of the members of Fabaceae family: A comprehensive review. Molecules, 2022, 27(12), 3863.
[http://dx.doi.org/10.3390/molecules27123863] [PMID: 35744986]

Pandrangi, S.L.; Chalumuri, S.S.; Garimella, S. Emerging therapeutic efficacy of alkaloids as anticancer agents. Ann. Rom. Soc. Cell Biol., 2022, 26(01), 64-74.

Bhattacharya, R.; Naitam, P. Green anticancer drugs-An review. Res. J. Pharmacogn. Phytochem., 2019, 11(4), 231-243.
[http://dx.doi.org/10.5958/0975-4385.2019.00040.2]

Levy, A. In CRC Handbook of Flowering; CRC Press, 2019, pp. 5-8.
[http://dx.doi.org/10.1201/9781351072564-3]

Waller, G. Alkaloid biology and metabolism in plants; Springer, 2012.

Evans, W.C. Trease and Evans’ pharmacognosy; Elsevier, 2009.

Dey, P.; Kundu, A.; Kumar, A.; Gupta, M. Recent advances in natural products analysis; Elsevier, 2020, pp. 505-567.
[http://dx.doi.org/10.1016/B978-0-12-816455-6.00015-9]

Phillipson, J.D. Phytochemistry and medicinal plants. Phytochemistry, 2001, 56(3), 237-243.
[http://dx.doi.org/10.1016/S0031-9422(00)00456-8] [PMID: 11243450]

Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100(1-2), 72-79.
[http://dx.doi.org/10.1016/j.jep.2005.05.011] [PMID: 16009521]

Jain, C.; Khatana, S.; Vijayvergia, R. Bioactivity of secondary metabolites of various plants: A review. Int. J. Pharm. Sci. Res., 2019, 10(2), 494-504.

Chen, J.J.; Chang, Y.L.; Teng, C.M.; Chen, I.S. Anti-platelet aggregation alkaloids and lignans from Hernandia nymphaeifolia. Planta Med., 2000, 66(3), 251-256.
[http://dx.doi.org/10.1055/s-2000-8562] [PMID: 10821052]

Gurung, P.; De, P. Spectrum of biological properties of Cinchona alkaloids: A brief review. J. Pharmacogn. Phytochem., 2017, 6(4), 162-166.

Oyama, T.; Isono, T.; Suzuki, Y.; Hayakawa, Y. Anti-nociceptive effects of aconiti tuber and its alkaloids. Am. J. Chin. Med., 1994, 22(2), 175-182.
[http://dx.doi.org/10.1142/S0192415X94000218] [PMID: 7992817]

Santos, F.A.; Rao, V.S.N. A study of the anti-pyretic effect of quinine, an alkaloid effective against cerebral malaria, on fever induced by bacterial endotoxin and yeast in rats. J. Pharm. Pharmacol., 2011, 50(2), 225-229.
[http://dx.doi.org/10.1111/j.2042-7158.1998.tb06180.x] [PMID: 9530992]

Fu, M.; Zou, B.; An, K.; Yu, Y.; Tang, D.; Wu, J.; Xu, Y.; Ti, H. Anti-asthmatic activity of alkaloid compounds from Pericarpium Citri Reticulatae (Citrus reticulata ‘Chachi’). Food Funct., 2019, 10(2), 903-911.
[http://dx.doi.org/10.1039/C8FO01753K] [PMID: 30694283]

Chemler, S. Phenanthroindolizidines and phenanthroquinolizidines: Promising alkaloids for anti-cancer therapy. Curr. Bioact. Compd., 2009, 5(1), 2-19.
[http://dx.doi.org/10.2174/157340709787580928] [PMID: 20160962]

Wangchuk, P.; Sastraruji, T.; Taweechotipatr, M.; Keller, P.A.; Pyne, S.G. Anti-inflammatory, anti-bacterial and anti-acetylcholinesterase activities of two isoquinoline alkaloids–Scoulerine and Cheilanthifoline. Nat. Prod. Commun., 2016, 11(12), 1934578X1601101207.
[http://dx.doi.org/10.1177/1934578X1601101207]

Sinha, S.; Sharma, A.; Reddy, P.H.; Rathi, B.; Prasad, N.V.S.R.K.; Vashishtha, A. Evaluation of phytochemical and pharmacological aspects of Holarrhena antidysenterica (Wall.): A comprehensive review. J. Pharm. Res., 2013, 6(4), 488-492.
[http://dx.doi.org/10.1016/j.jopr.2013.04.004]

Arora, S.; Narayan, P.; Osgood, C.L.; Wedam, S.; Prowell, T.M.; Gao, J.J.; Shah, M.; Krol, D.; Wahby, S.; Royce, M.; Ghosh, S.; Philip, R.; Ison, G.; Berman, T.; Brus, C.; Bloomquist, E.W.; Fiero, M.H.; Tang, S.; Pazdur, R.; Ibrahim, A.; Amiri-Kordestani, L.; Beaver, J.A.US FDA drug approvals for breast cancer: A decade in review. Clin. Cancer Res., 2022, 28(6), 1072-1086.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-2600] [PMID: 34711632]

Rafferty, C.M. Everolimus: A new treatment for hormone receptor–positive advanced breast cancer. TON, 2013, 6(4)

Chang, D.Y.; Ma, W.L.; Lu, Y.S. Role of Alpelisib in the treatment of PIK3CA-mutated breast cancer: Patient selection and clinical perspectives. Ther. Clin. Risk Manag., 2021, 17, 193-207.
[http://dx.doi.org/10.2147/TCRM.S251668] [PMID: 33707948]

Narayan, P.; Prowell, T.M.; Gao, J.J.; Fernandes, L.L.; Li, E.; Jiang, X.; Qiu, J.; Fan, J.; Song, P.; Yu, J.; Zhang, X.; King-Kallimanis, B.L.; Chen, W.; Ricks, T.K.; Gong, Y.; Wang, X.; Windsor, K.; Rhieu, S.Y.; Geiser, G.; Banerjee, A.; Chen, X.; Reyes Turcu, F.; Chatterjee, D.K.; Pathak, A.; Seidman, J.; Ghosh, S.; Philip, R.; Goldberg, K.B.; Kluetz, P.G.; Tang, S.; Amiri-Kordestani, L.; Theoret, M.R.; Pazdur, R.; Beaver, J.A. FDA approval summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin. Cancer Res., 2021, 27(7), 1842-1849.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-3652] [PMID: 33168657]

André, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H.S.; Iwata, H.; Conte, P.; Mayer, I.A.; Kaufman, B.; Yamashita, T.; Lu, Y.S.; Inoue, K.; Takahashi, M.; Pápai, Z.; Longin, A.S.; Mills, D.; Wilke, C.; Hirawat, S.; Juric, D. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med., 2019, 380(20), 1929-1940.
[http://dx.doi.org/10.1056/NEJMoa1813904] [PMID: 31091374]

Johnson, K.C.C.; Quiroga, D.; Sudheendra, P.; Wesolowski, R. Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens. Expert Rev. Anticancer Ther., 2022, 22(5), 505-522.
[http://dx.doi.org/10.1080/14737140.2022.2063844] [PMID: 35389302]

Narayan, P.; Osgood, C.L.; Singh, H.; Chiu, H.J.; Ricks, T.K.; Chiu Yuen Chow, E.; Qiu, J.; Song, P.; Yu, J.; Namuswe, F.; Guiterrez-Lugo, M.; Hou, S.; Pierce, W.F.; Goldberg, K.B.; Tang, S.; Amiri-Kordestani, L.; Theoret, M.R.; Pazdur, R.; Beaver, J.A. FDA approval summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-Positive breast cancer. Clin. Cancer Res., 2021, 27(16), 4478-4485.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-4557] [PMID: 33753456]

Saura, C.; Oliveira, M.; Feng, Y.H.; Dai, M.S.; Chen, S.W.; Hurvitz, S.A.; Kim, S.B.; Moy, B.; Delaloge, S.; Gradishar, W.; Masuda, N.; Palacova, M.; Trudeau, M.E.; Mattson, J.; Yap, Y.S.; Hou, M.F.; De Laurentiis, M.; Yeh, Y.M.; Chang, H.T.; Yau, T.; Wildiers, H.; Haley, B.; Fagnani, D.; Lu, Y.S.; Crown, J.; Lin, J.; Takahashi, M.; Takano, T.; Yamaguchi, M.; Fujii, T.; Yao, B.; Bebchuk, J.; Keyvanjah, K.; Bryce, R.; Brufsky, A. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Phase III NALA trial. J. Clin. Oncol., 2020, 38(27), 3138-3149.
[http://dx.doi.org/10.1200/JCO.20.00147] [PMID: 32678716]

Shah, M.; Wedam, S.; Cheng, J.; Fiero, M.H.; Xia, H.; Li, F.; Fan, J.; Zhang, X.; Yu, J.; Song, P.; Chen, W.; Ricks, T.K.; Chen, X.H.; Goldberg, K.B.; Gong, Y.; Pierce, W.F.; Tang, S.; Theoret, M.R.; Pazdur, R.; Amiri-Kordestani, L.; Beaver, J.A. FDA approval summary: Tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin. Cancer Res., 2021, 27(5), 1220-1226.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-2701] [PMID: 33055172]

Crespo, J.; Sun, H.; Wu, J.; Ding, Q.Q.; Tang, G.; Robinson, M.K.; Chen, H.; Sahin, A.A.; Lim, B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One, 2020, 15(11), e0241775.
[http://dx.doi.org/10.1371/journal.pone.0241775] [PMID: 33180796]

Markham, A. Margetuximab: First approval. Drugs, 2021, 81(5), 599-604.
[http://dx.doi.org/10.1007/s40265-021-01485-2] [PMID: 33761116]

Rugo, H.S. Im, S.A.; Cardoso, F.; Cortés, J.; Curigliano, G.; Musolino, A.; Pegram, M.D.; Wright, G.S.; Saura, C.; Escrivá-de-Romaní, S.; De Laurentiis, M.; Levy, C.; Brown-Glaberman, U.; Ferrero, J.M.; de Boer, M.; Kim, S.B.; Petráková, K.; Yardley, D.A.; Freedman, O.; Jakobsen, E.H.; Kaufman, B.; Yerushalmi, R.; Fasching, P.A.; Nordstrom, J.L.; Bonvini, E.; Koenig, S.; Edlich, S.; Hong, S.; Rock, E.P.; Gradishar, W.J. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol., 2021, 7(4), 573-584.
[http://dx.doi.org/10.1001/jamaoncol.2020.7932] [PMID: 33480963]

Narayan, P.; Wahby, S.; Gao, J.J.; Amiri-Kordestani, L.; Ibrahim, A.; Bloomquist, E.; Tang, S.; Xu, Y.; Liu, J.; Fu, W.; Song, P.; King-Kallimanis, B.L.; Hou, S.; Gong, Y.; Kalavar, S.; Ghosh, S.; Philip, R.; Goldberg, K.B.; Theoret, M.R.; Blumenthal, G.M.; Kluetz, P.G.; Sridhara, R.; Pazdur, R.; Beaver, J.A. FDA approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin. Cancer Res., 2020, 26(10), 2284-2289.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-3545] [PMID: 32001481]

McCann, K.E.; Hurvitz, S.A.; McAndrew, N. Advances in targeted therapies for triple-negative breast cancer. Drugs, 2019, 79(11), 1217-1230.
[http://dx.doi.org/10.1007/s40265-019-01155-4] [PMID: 31254268]

Cortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Holgado, E.; Iwata, H.; Masuda, N.; Otero, M.T.; Gokmen, E.; Loi, S.; Guo, Z.; Zhao, J.; Aktan, G.; Karantza, V.; Schmid, P.; Luis, F.; Gonzalo, G.A.; Diego, K.; Ruben, K.; Matias, M.; Mirta, V.; Sally, B-H.; Stephen, B.; Philip, C.; Sherene, L.; Dhanusha, S.; Andrea, G.; Donatienne, T.; Carlos, B.; Leandro, B.; Fabiano, C.; Ruffo, F.J.; Roberto, H.; Domicio Carvalho, L.; Fernando Cezar Toniazzi, L.; Roberto Odebrecht, R.; Antonio Orlando, S.N.; Felipe, S.; David, C.; Danielle, C.; Cristiano, F.; Xinni, S.; Joanne, Y.; Alejandro, A.; Carlos, G.; Claudio, S.; Cesar, S.; Eduardo, Y.; Alvaro, G.D.; Jesus, S.; Petra, H.; Zdenek, K.; Bohuslav, M.; Katarina, P.; Jana, P.; Vesna, G.; Erik, J.; Jeanette, J.; Soren, L.; Tamas, L.; Herve, B.; Isabelle, D.; Anthony, G.; Anne-Claire, H-B.; Luis, T.; Jens-Uwe, B.; Peter, F.; Dirk, F.; Nadia, H.; Jens, H.; Anna, K.F.S.; Christian, K.; Sibylle, L.; Diana, L.; Tjoung-Won, P-S.; Raquel Von, S.; Pauline, W.; Louis, C.; Ava, K.; Kai Cheong Roger, N.; Peter, A.; Tibor, C.; Zsuzsanna, K.; Laszlo, L.; Karoly, M.; Gabor, R.; John, C.; Catherine, K.; Seamus, O.R.; Saverio, C.; Antonietta, D.A.; Enrico, R.; Tomoyuki, A.; Takaaki, F.; Kenichi, I.; Takashi, I.; Yoshinori, I.; Tsutomu, I.; Hiroji, I.; Yoshimasa, K.; Koji, M.; Yasuo, M.; Hirofumi, M.; Seigo, N.; Naoki, N.; Shoichiro, O.; Akihiko, O.; Yasuaki, S.; Eiji, S.; Masato, T.; Yuko, T.; Kenji, T.; Koichiro, T.; Junichiro, W.; Naohito, Y.; Yutaka, Y.; Teruo, Y.; Anita, B.; Mastura, M.Y.; Angel, G.V.; Alejandro, J.R.; Jorge, M.R.; Flavia, M-V.; Jessica, R.C.; Karin, B.; Vivianne, T-H.; David, P.; Ewa, C.; Ewa, N-Z.; Zbigniew, N.; Barbara, R.; Joanna, S.; Cezary, S.; Rafal, T.; Bogdan, Z.; Alexander, A.; Natalia, F.; Oleg, L.; Andrey, M.; Vladimir, M.; Guzel, M.; Jin Hee, A.; Seock-Ah, I.; Keun Seok, L.; Kwong Hwa, P.; Yeon Hee, P.; Begona, B.H.; Javier, C.; Josefina, C.J.; Luis, C.M.; Jose, G.S.; Maria, G.; Esther, H.; Esther, Z.A.; Chien-Ting, L.; Mei-Ching, L.; Chiun-Sheng, H.; Chao-Jung, T.; Ling-Ming, T.; Cagatay, A.; Gul, B.; Irfan, C.; Erhan, G.; Seyda, G.; Nil, M.M.; Mustafa, O.; Ozgur, O.; Sinan, Y.; Steve, C.; Janine, G.; Iain, M.P.; Peter, S.; Nicholas, T.; Mark, T.; Christopher, T.; Duncan, W.; Hryhoriy, A.; Oleksandr, B.; Igor, B.; Oleksii, K.; Olena, K.; Hanna, K.; Anna, K.; Iurii, L.; Alla, N.; Natalya, O.; Olga, P.; Andrii, R.; Sergii, S.; Yaroslav, S.; Dmytro, T.; Grygorii, U.; Ihor, V.; Sibel, B.; Madhu, C.; Michael, C.; Patrick, C.; Scott, C.; Jennifer, D.; Keerthi, G.; Jeffrey, H.; Kent, H.; William, I.; Randa, L.; Janice, L.; Raul, M.; Susan, M.; Rita, N.; Ira, O.; Coral, O.; Timothy, P.; Amit, P.; Brian, P.; Hope, R.; Irina, R.; Michael, S.; Robert, S.; Michael, S.; Laura, S.; Bradley, S.; Michaela, T.; Frances, V-A. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 2020, 396(10265), 1817-1828.
[http://dx.doi.org/10.1016/S0140-6736(20)32531-9] [PMID: 33278935]

Wahby, S.; Fashoyin-Aje, L.; Osgood, C.L.; Cheng, J.; Fiero, M.H.; Zhang, L.; Tang, S.; Hamed, S.S.; Song, P.; Charlab, R.; Dorff, S.E.; Ricks, T.K.; Barnett-Ringgold, K.; Dinin, J.; Goldberg, K.B.; Theoret, M.R.; Pazdur, R.; Amiri-Kordestani, L.; Beaver, J.A. FDA approval summary: Accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin. Cancer Res., 2021, 27(7), 1850-1854.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-3119] [PMID: 33168656]

Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; Wu, W.; Goessl, C.; Runswick, S.; Conte, P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med., 2017, 377(6), 523-533.
[http://dx.doi.org/10.1056/NEJMoa1706450] [PMID: 28578601]

Yardley, D.A.; McCleod, M.; Schreiber, F.; Murphy, P.; Patton, J.; Thompson, D.S.; Shastry, M.; Rubin, M.; Melnik, M.; Burris, H.A.; Hainsworth, J.D. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest., 2010, 28(9), 925-931.
[http://dx.doi.org/10.3109/07357907.2010.496755] [PMID: 20690806]

Rampogu, S.; Balasubramaniyam, T.; Lee, J.H. Phytotherapeutic applications of alkaloids in treating breast cancer. Biomed. Pharmacother., 2022, 155, 113760.
[http://dx.doi.org/10.1016/j.biopha.2022.113760] [PMID: 36271547]

An, B.; Zhang, S.; Hu, J.; Pan, T.; Huang, L.; Tang, J.C.; Li, X.; Chan, A.S.C. The design, synthesis and evaluation of selenium-containing 4-anilinoquinazoline hybrids as anticancer agents and a study of their mechanism. Org. Biomol. Chem., 2018, 16(25), 4701-4714.
[http://dx.doi.org/10.1039/C8OB00875B] [PMID: 29900452]

Arya, K.R.; Rajendra Prasad, K.J. Rational eco-compatible synthesis and biological screening of new highly functionalized pyrido[2,3- a]carbazole derivatives: A novel class of antioxidant and anticancer agents. Synth. Commun., 2018, 48(12), 1465-1481.
[http://dx.doi.org/10.1080/00397911.2018.1455211]

Parrino, B.; Ullo, S.; Attanzio, A.; Cascioferro, S.; Spanò, V.; Carbone, A.; Montalbano, A.; Barraja, P.; Cirrincione, G.; Tesoriere, L.; Diana, P. Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity. Eur. J. Med. Chem., 2018, 158, 236-246.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.017] [PMID: 30218909]

Chate, A.V.; Kamdi, S.P.; Bhagat, A.N.; Jadhav, C.K.; Nipte, A.; Sarkate, A.P.; Tiwari, S.V.; Gill, C.H. Design, synthesis and SAR study of novel spiro [pyrimido[5,4-b]quinoline-10,5′-pyrrolo[2,3-d]pyrimidine] derivatives as promising anticancer agents. J. Heterocycl. Chem., 2018, 55(10), 2297-2302.
[http://dx.doi.org/10.1002/jhet.3286]

Chen, S.; Yong, T.; Xiao, C.; Su, J.; Zhang, Y.; Jiao, C.; Xie, Y. Pyrrole alkaloids and ergosterols from Grifola frondosa exert anti-α-glucosidase and anti-proliferative activities. J. Funct. Foods, 2018, 43, 196-205.
[http://dx.doi.org/10.1016/j.jff.2018.02.007]

Fang, J.; Huang, T.; Xia, M.; Deng, L.; Hao, X.; Wang, Y.; Mu, S. Design and synthesis of novel monoterpenoid indole alkaloid-like analogues and their antitumour activities in vitro. Org. Biomol. Chem., 2018, 16(16), 3026-3037.
[http://dx.doi.org/10.1039/C8OB00677F] [PMID: 29634066]

Ghanbarimasir, Z.; Bekhradnia, A.; Morteza-Semnani, K.; Rafiei, A.; Razzaghi-Asl, N.; Kardan, M. Design, synthesis, biological assessment and molecular docking studies of new 2-aminoimidazole-quinoxaline hybrids as potential anticancer agents. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2018, 194, 21-35.
[http://dx.doi.org/10.1016/j.saa.2017.12.063] [PMID: 29310028]

Jha, K.K.; Dutta, S.; Sar, S.; Sen, S.; Munshi, P. Harnessing sun for catalyst and sensitizer free regio- and stereo-selective [2+2] cycloaddition. Tetrahedron, 2018, 74(51), 7326-7334.
[http://dx.doi.org/10.1016/j.tet.2018.10.065]

Guo, L.; Chen, W.; Cao, R.; Fan, W.; Ma, Q.; Zhang, J.; Dai, B. Synthesis and structure-activity relationships of asymmetric dimeric β-carboline derivatives as potential antitumor agents. Eur. J. Med. Chem., 2018, 147, 253-265.
[http://dx.doi.org/10.1016/j.ejmech.2018.02.003] [PMID: 29448140]

Kumari, P.; Narayana, C.; Dubey, S.; Gupta, A.; Sagar, R. Stereoselective synthesis of natural product inspired carbohydrate fused pyrano[3,2- c]quinolones as antiproliferative agents. Org. Biomol. Chem., 2018, 16(12), 2049-2059.
[http://dx.doi.org/10.1039/C7OB03186F] [PMID: 29411817]

Chen, K.; Zhang, Y.L.; Fan, J.; Ma, X.; Qin, Y.J.; Zhu, H.L. Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation. Eur. J. Med. Chem., 2018, 156, 722-737.
[http://dx.doi.org/10.1016/j.ejmech.2018.07.044] [PMID: 30041136]

Lan, J.; Huang, L.; Lou, H.; Chen, C.; Liu, T.; Hu, S.; Yao, Y.; Song, J.; Luo, J.; Liu, Y.; Xia, B.; Xia, L.; Zeng, X.; Ben-David, Y.; Pan, W. Design and synthesis of novel C14-urea-tetrandrine derivatives with potent anti-cancer activity. Eur. J. Med. Chem., 2018, 143, 1968-1980.
[http://dx.doi.org/10.1016/j.ejmech.2017.11.007] [PMID: 29133049]

Li, W.S.; Yang, Y.; Liu, J.J.; Shen, L.; Shi, Z.; Wu, J. Scaffold diversity-oriented synthesis of limonoid dimers: Discovery of an axially chiral agent with in vivo anti-breast cancer activity. Org. Chem. Front., 2018, 5(7), 1079-1091.
[http://dx.doi.org/10.1039/C8QO00154E]

Budovská, M.; Baláž, M.; Mezencev, R.; Tischlerová, V.; Zigová, M.; Mojžiš, J. Design, synthesis and anticancer activity of trifluoromethylphenylamino substituted spiroindoles. J. Fluor. Chem., 2018, 216, 24-32.
[http://dx.doi.org/10.1016/j.jfluchem.2018.09.011]

Li, Y.; Yan, W.; Yang, J.; Yang, Z.; Hu, M.; Bai, P.; Tang, M.; Chen, L. Discovery of novel β-carboline/acylhydrazone hybrids as potent antitumor agents and overcome drug resistance. Eur. J. Med. Chem., 2018, 152, 516-526.
[http://dx.doi.org/10.1016/j.ejmech.2018.05.003] [PMID: 29754076]

Murali, K.; Sparkes, H.A.; Rajendra Prasad, K.J. Regio- and stereoselective synthesis of dispirooxindole-pyrrolocarbazole hybrids via 1,3-dipolar cycloaddition reactions: Cytotoxic activity and SAR studies. Eur. J. Med. Chem., 2018, 143, 292-305.
[http://dx.doi.org/10.1016/j.ejmech.2017.11.039] [PMID: 29197734]

Satheeshkumar, R.; Muthusankar, A.; Edatt, L.; Sameer Kumar, V.B.; Sparkes, H.A.; Rajendra Prasad, K.J. Synthesis of heteroannulated cyclopent[ b]indoles: Exploration of in vitro cytotoxicity and molecular docking studies. Synth. Commun., 2018, 48(4), 447-461.
[http://dx.doi.org/10.1080/00397911.2017.1407792]

Sathish, M.; Kavitha, B.; Nayak, V.L.; Tangella, Y.; Ajitha, A.; Nekkanti, S.; Alarifi, A.; Shankaraiah, N.; Nagesh, N.; Kamal, A. Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors. Eur. J. Med. Chem., 2018, 144, 557-571.
[http://dx.doi.org/10.1016/j.ejmech.2017.12.055] [PMID: 29289881]

Thirunavukkarasu, T.; Sparkes, H.A.; Natarajan, K. Quinoline based Pd(II) complexes: Synthesis, characterization and evaluation of DNA/protein binding, molecular docking and in vitro anticancer activity. Inorg. Chim. Acta, 2018, 482, 229-239.
[http://dx.doi.org/10.1016/j.ica.2018.06.003]

Stefański, T.; Mikstacka, R.; Kurczab, R.; Dutkiewicz, Z.; Kucińska, M.; Murias, M.; Zielińska-Przyjemska, M.; Cichocki, M.; Teubert, A.; Kaczmarek, M.; Hogendorf, A.; Sobiak, S. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents. Eur. J. Med. Chem., 2018, 144, 797-816.
[http://dx.doi.org/10.1016/j.ejmech.2017.11.050] [PMID: 29291446]

Hekal, M.H.; Abu El-Azm, F.S.M.; Sallam, H.A. Synthesis, spectral characterization, and in vitro biological evaluation of some novel isoquinolinone-based heterocycles as potential antitumor agents. J. Heterocycl. Chem., 2019, 56(3), 795-803.
[http://dx.doi.org/10.1002/jhet.3448]

Bondock, S.; Alqahtani, S.; Fouda, A.M. Convenient synthesis and antitumor evaluation of some new 9-ethyl-3-(hetaryl)carbazoles. Synth. Commun., 2019, 49(17), 2188-2202.
[http://dx.doi.org/10.1080/00397911.2019.1616759]

Pan, X.; Liang, L.; Si, R.; Wang, J.; Zhang, Q.; Zhou, H.; Zhang, L.; Zhang, J. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol. Eur. J. Med. Chem., 2019, 163, 1-9.
[http://dx.doi.org/10.1016/j.ejmech.2018.11.042] [PMID: 30503935]

Mustafa, M.; Anwar, S.; Elgamal, F.; Ahmed, E.R.; Aly, O.M. Potent combretastatin A-4 analogs containing 1,2,4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study. Eur. J. Med. Chem., 2019, 183, 111697.
[http://dx.doi.org/10.1016/j.ejmech.2019.111697] [PMID: 31536891]

Pang, Y.; Lin, H.; Ou, C.; Cao, Y.; An, B.; Yan, J.; Li, X. Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization in vitro and in vivo. Eur. J. Med. Chem., 2019, 182, 111670.
[http://dx.doi.org/10.1016/j.ejmech.2019.111670] [PMID: 31499359]

Patel, O.P.S.; Arun, A.; Singh, P.K.; Saini, D.; Karade, S.S.; Chourasia, M.K.; Konwar, R.; Yadav, P.P. Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt/mTOR in breast cancer cells. Eur. J. Med. Chem., 2019, 167, 226-244.
[http://dx.doi.org/10.1016/j.ejmech.2019.02.003] [PMID: 30772606]

Ceramella, J.; Caruso, A.; Occhiuzzi, M.A.; Iacopetta, D.; Barbarossa, A.; Rizzuti, B.; Dallemagne, P.; Rault, S.; El-Kashef, H.; Saturnino, C.; Grande, F.; Sinicropi, M.S. Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization. Eur. J. Med. Chem., 2019, 181, 111583.
[http://dx.doi.org/10.1016/j.ejmech.2019.111583] [PMID: 31400710]

Varró, G.; Pálchuber, P.; Pogrányi, B.; Simon, A.; Hegedűs, L.; Kádas, I. (±)-trans-Dihydronarciclasine and (±)-trans-dihydrolycoricidine analogues modified in their ring A: Evaluation of their anticancer activity and a SAR study. Eur. J. Med. Chem., 2019, 173, 76-89.
[http://dx.doi.org/10.1016/j.ejmech.2019.04.010] [PMID: 30986573]

Piechowska, K.; Świtalska, M.; Cytarska, J.; Jaroch, K.; Łuczykowski, K.; Chałupka, J.; Wietrzyk, J.; Misiura, K.; Bojko, B.; Kruszewski, S.; Łączkowski, K.Z. Discovery of tropinone-thiazole derivatives as potent caspase 3/7 activators, and noncompetitive tyrosinase inhibitors with high antiproliferative activity: Rational design, one-pot tricomponent synthesis, and lipophilicity determination. Eur. J. Med. Chem., 2019, 175, 162-171.
[http://dx.doi.org/10.1016/j.ejmech.2019.05.006] [PMID: 31082763]

Li, L.; Quan, D.; Chen, J.; Ding, J.; Zhao, J.; Lv, L.; Chen, J. Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents. Eur. J. Med. Chem., 2019, 184, 111732.
[http://dx.doi.org/10.1016/j.ejmech.2019.111732] [PMID: 31610372]

Venkatesh, R.; Kasaboina, S.; Jain, N.; Janardhan, S.; Holagunda, U.D.; Nagarapu, L. Design and synthesis of novel sulphamide tethered quinazolinone hybrids as potential antitumor agents. J. Mol. Struct., 2019, 1181, 403-411.
[http://dx.doi.org/10.1016/j.molstruc.2018.12.098]

Venkat Swamy, P.; Kiran Kumar, V.; Radhakrishnam Raju, R.; Venkata Reddy, R.; Chatterjee, A.; Kiran, G.; Sridhar, G. Amide derivatives of 4-azaindole: Design, synthesis, and EGFR targeting anticancer agents. Synth. Commun., 2020, 50(1), 71-84.
[http://dx.doi.org/10.1080/00397911.2019.1683206]

Yavuz, S.Ç.; Akkoç, S.; Sarıpınar, E. The cytotoxic activities of imidazole derivatives prepared from various guanylhydrazone and phenylglyoxal monohydrate. Synth. Commun., 2019, 49(22), 3198-3209.
[http://dx.doi.org/10.1080/00397911.2019.1661481]

Shen, Q.K.; Deng, H.; Wang, S.B.; Tian, Y.S.; Quan, Z.S. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway. Eur. J. Med. Chem., 2019, 173, 15-31.
[http://dx.doi.org/10.1016/j.ejmech.2019.04.005] [PMID: 30981113]

Mahanti, S.; Sunkara, S.; Bhavani, R. Synthesis, biological evaluation and computational studies of fused acridine containing 1,2,4-triazole derivatives as anticancer agents. Synth. Commun., 2019, 49(13), 1729-1740.
[http://dx.doi.org/10.1080/00397911.2019.1608450]

Nishtala, V.B.; Gandamalla, D.; Yellu, N.R.; Basavoju, S. Synthesis of spirooxindoles promoted by the deep eutectic solvent, ZnCl2+ urea via the pseudo four-component reaction: Anticancer, antioxidant, and molecular docking studies. Synth. Commun., 2019, 49(20), 2671-2682.
[http://dx.doi.org/10.1080/00397911.2019.1639193]

Mirzaei, S.; Eisvand, F.; Hadizadeh, F.; Mosaffa, F.; Ghasemi, A.; Ghodsi, R. Design, synthesis and biological evaluation of novel 5,6,7-trimethoxy-N-aryl-2-styrylquinolin-4-amines as potential anticancer agents and tubulin polymerization inhibitors. Bioorg. Chem., 2020, 98, 103711.
[http://dx.doi.org/10.1016/j.bioorg.2020.103711] [PMID: 32179282]

Donthiboina, K.; Anchi, P.; Gurram, S.; Sai, M. G.; Lakshmi Uppu, J.; Godugu, C.; Shankaraiah, N.; Kamal, A. Synthesis and biological evaluation of substituted N-(2-(1H-benzo[d]imidazol-2-yl)phenyl)cinnamides as tubulin polymerization inhibitors. Bioorg. Chem., 2020, 103, 104191.
[http://dx.doi.org/10.1016/j.bioorg.2020.104191] [PMID: 32891862]

George, R.F.; Kandeel, M.; El-Ansary, D.Y.; El Kerdawy, A.M. Some 1,3,5-trisubstituted pyrazoline derivatives targeting breast cancer: Design, synthesis, cytotoxic activity, EGFR inhibition and molecular docking. Bioorg. Chem., 2020, 99, 103780.
[http://dx.doi.org/10.1016/j.bioorg.2020.103780] [PMID: 32224337]

Gür, M.; Yerlikaya, S.; Şener, N.; Özkınalı, S.; Baloglu, M.C.; Gökçe, H.; Altunoglu, Y.C.; Demir, S.; Şener, İ. Antiproliferative-antimicrobial properties and structural analysis of newly synthesized Schiff bases derived from some 1,3,4-thiadiazole compounds. J. Mol. Struct., 2020, 1219, 128570.
[http://dx.doi.org/10.1016/j.molstruc.2020.128570]

Desai, S.; Desai, V.; Shingade, S. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors. Bioorg. Chem., 2020, 94, 103382.
[http://dx.doi.org/10.1016/j.bioorg.2019.103382] [PMID: 31662214]

Mirzaei, S.; Hadizadeh, F.; Eisvand, F.; Mosaffa, F.; Ghodsi, R. Synthesis, structure-activity relationship and molecular docking studies of novel quinoline-chalcone hybrids as potential anticancer agents and tubulin inhibitors. J. Mol. Struct., 2020, 1202, 127310.
[http://dx.doi.org/10.1016/j.molstruc.2019.127310]

Kouba, S.; Braire, J.; Félix, R.; Chantôme, A.; Jaffrès, P.A.; Lebreton, J.; Dubreuil, D.; Pipelier, M.; Zhang, X.; Trebak, M.; Vandier, C.; Mathé-Allainmat, M.; Potier-Cartereau, M. Lipidic synthetic alkaloids as SK3 channel modulators. Synthesis and biological evaluation of 2-substituted tetrahydropyridine derivatives with potential anti-metastatic activity. Eur. J. Med. Chem., 2020, 186, 111854.
[http://dx.doi.org/10.1016/j.ejmech.2019.111854] [PMID: 31753515]

Zhou, S.; Huang, G. Design, synthesis and biological evaluation of novel 7H-benzo [c] [1, 3] dioxolo [4, 5-f] chromen-7-one derivatives with potential anti-tumor activity. Bioorg. Chem., 2020, 105, 104381.
[http://dx.doi.org/10.1016/j.bioorg.2020.104381] [PMID: 33113412]

Xue, H.; Svatek, H.; Bertonha, A.F.; Reisenauer, K.; Robinson, J.; Kim, M.; Ingros, A.; Ho, M.; Taube, J.; Romo, D. Synthesis of agelastatin A and derivatives premised on a hidden symmetry element leading to analogs displaying anticancer activity. Tetrahedron, 2021, 94, 132340.
[http://dx.doi.org/10.1016/j.tet.2021.132340] [PMID: 35663119]

Eissa, I.H.; Dahab, M.A.; Ibrahim, M.K.; Alsaif, N.A.; Alanazi, A.Z.; Eissa, S.I.; Mehany, A.B.M.; Beauchemin, A.M. Design and discovery of new antiproliferative 1,2,4-triazin-3(2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site. Bioorg. Chem., 2021, 112, 104965.
[http://dx.doi.org/10.1016/j.bioorg.2021.104965] [PMID: 34020238]

Elimam, D.M.; Elgazar, A.A.; Bonardi, A.; Abdelfadil, M.; Nocentini, A.; El-Domany, R.A.; Abdel-Aziz, H.A.; Badria, F.A.; Supuran, C.T.; Eldehna, W.M. Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation. Eur. J. Med. Chem., 2021, 225, 113800.
[http://dx.doi.org/10.1016/j.ejmech.2021.113800] [PMID: 34482273]

Chen, Y.Y.; Bai, Y.P.; Li, B.; Zhao, X.B.; Yang, C.J.; Liu, Y.Q.; Gao, J.M.; Guo, J.; Li, C.; Peng, J.W.; Zhao, Z.M.; Zhang, Z.J.; Xu, C.R. Design and synthesis of novel 20(S)-α-aminophosphonate derivatives of camptothecin as potent antitumor agents. Bioorg. Chem., 2021, 114, 105065.
[http://dx.doi.org/10.1016/j.bioorg.2021.105065] [PMID: 34174631]

Hassan, S.M.; Morsy, J.M.; Hassanin, H.M.; Othman, E.S. Synthesis and cytotoxic evaluation of novel brominated N-alkyl pyrano[3,2-c]quinolinones. J. Heterocycl. Chem., 2021, 58(1), 305-314.
[http://dx.doi.org/10.1002/jhet.4169]

Kulkarni, M.R.; Lad, N.P.; Khedkar, V.M.; Gaikwad, N.D. Synthesis, in vitro cytotoxicity, and molecular docking study of novel 3, 4-dihydroisoquinolin-1(2H)-one based piperlongumine analogues. J. Heterocycl. Chem., 2021, 58(6), 1359-1370.
[http://dx.doi.org/10.1002/jhet.4264]

Luan, S.; Gao, Y.; Liang, X.; Zhang, L.; Yin, L.; He, C.; Liu, S.; Yin, Z.; Yue, G.; Zou, Y.; Li, L.; Song, X.; Lv, C.; Zhang, W.; Jing, B. Synthesis and structure-activity relationship of lipo-diterpenoid alkaloids with potential target of topoisomerase IIα for breast cancer treatment. Bioorg. Chem., 2021, 109, 104699.
[http://dx.doi.org/10.1016/j.bioorg.2021.104699] [PMID: 33611138]

Sun, J.; Wang, J.; Wang, X.; Hu, X.; Cao, H.; Bai, J.; Li, D.; Hua, H. Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer. Bioorg. Med. Chem., 2021, 45, 116341.
[http://dx.doi.org/10.1016/j.bmc.2021.116341] [PMID: 34365102]

Al-Nemari, R.; Bacha, A.B.; Al-Senaidy, A.; Almutairi, M.H.; Arafah, M.; Al-Saran, H.; Abutaha, N.; Semlali, A. Cytotoxic effects of Annona squamosa leaves against breast cancer cells via apoptotic signaling proteins. J. King Saud Univ. Sci., 2022, 34(4), 102013.
[http://dx.doi.org/10.1016/j.jksus.2022.102013]

Yang, P.; Cheng, Y.; Huang, X.; Huang, B.; Yi, L.; He, H.; Xie, Y. Identification of a new benzophenanthridine alkaloid from Eomecon chionantha induced necroptosis in breast cancer cells. Nat. Prod. Res., 2023, 37(6), 912-918.
[http://dx.doi.org/10.1080/14786419.2022.2096606] [PMID: 35801972]